Download New Targeting in The Reversal of Resistant Glioblastomas Ebook PDF

New Targeting in The Reversal of Resistant Glioblastomas

New Targeting in The Reversal of Resistant Glioblastomas
A Book

by Ali Syed Arbab

  • Publisher : Academic Press
  • Release : 2021-03-05
  • Pages : 202
  • ISBN : 0128232765
  • Language : En, Es, Fr & De
GET BOOK

New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field. Explains the effect of bone marrow derived cells on the development of resistance to clinically practiced therapies Provides information on the availability of alternate therapies for recurrent glioblastoma when standard practices have failed Discusses targeting tumor microenvironment using available FDA approved drugs as an alternative treatment strategy for glioblastoma

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies
A Book

by Ramasamy Paulmurugan,Tarik F. Massoud

  • Publisher : Academic Press
  • Release : 2021-06-25
  • Pages : 828
  • ISBN : 0128215682
  • Language : En, Es, Fr & De
GET BOOK

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies brings current knowledge from an international team of experts on the science and clinical management of glioblastoma chemoresistance. The book discusses topics such as molecular mechanisms of chemoresistance, experimental models to study chemoresistance, chemoresistance to drugs other than Temozolomide, and specific strategies to reverse chemoresistance. Additionally, it encompasses information on how to mitigate chemoresistance by targeted enhancement of p53 function. This book is a valuable resource for cancer researchers, oncologists, neuro-oncologists and other members of the biomedical field. Glioblastoma (GBM) is the most invasive and malignant primary brain tumor in humans with poor survival after diagnosis, therefore it is imperative that molecular and cellular mechanisms behind therapy resistant GBM cells, as well as the therapeutic strategies available to counter the resistance are comprehensively understood. Provides comprehensive, core knowledge related to the entire discipline of glioblastoma chemoresistance, from its many etiological mechanisms, to specific strategies to reverse resistance Presents current information from an international team of experts on the basic science, pre-clinical research, and clinical management of glioblastoma chemoresistance Discusses molecular and cellular mechanisms behind therapy resistant glioblastoma cells, as well as the therapeutic strategies available to counter this resistance

Overcoming Drug Resistance in Gynecologic Cancers

Overcoming Drug Resistance in Gynecologic Cancers
A Book

by Anonim

  • Publisher : Academic Press
  • Release : 2021-08-11
  • Pages : 388
  • ISBN : 0128243007
  • Language : En, Es, Fr & De
GET BOOK

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers. Provides a comprehensive resource with all the details needed for readers to understand and follow information Encompasses schematics, diagrams and flow charts in all chapters to help readers easily follow critical information Presents tables and figures especially developed to summarize the information with appropriate statistical rigor and to show details of clinical specimens such as pathological, radiological characteristics, and/or laboratory biomarkers

Therapeutic Strategies to Overcome ALK Resistance in Cancer

Therapeutic Strategies to Overcome ALK Resistance in Cancer
A Book

by Luc Friboulet

  • Publisher : Academic Press
  • Release : 2021-01-18
  • Pages : 216
  • ISBN : 0128217790
  • Language : En, Es, Fr & De
GET BOOK

Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field. This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment. Explains the biology of ALK RTK, focusing on its tissue expression, structure and functionality Presents an overview of current treatments and the benefits of ALK TKI in lung and other cancer types, such as ALCL, neuroblastoma and inflammatory myofibroblastic tumor Encompasses information on systemic treatments other than TKI, including chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC

Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies

Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies
A Book

by Chi Hin Cho,Tao Hu

  • Publisher : Academic Press
  • Release : 2020-05-24
  • Pages : 240
  • ISBN : 0128199385
  • Language : En, Es, Fr & De
GET BOOK

Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies, Volume Eight, summarizes the molecular mechanisms of drug resistance in colorectal cancer, along with the most up-to-date therapeutic strategies available. The book discusses reasons why colorectal tumors become refractory during the progression of the disease, but also explains how drug resistance occurs during chemotherapy. In addition, users will find the current therapeutic strategies used by clinicians in their practice in treating colorectal cancer. The combination of conventional anticancer drugs with chemotherapy-sensitizing agents plays a pivotal role in improving the outcome of colorectal cancer patients, in particular those with drug-resistant cancer cells. From a clinical point-of-view, the content of this book provides clinicians with updated therapeutic strategies for a better choice of drugs for drug-resistant colorectal cancer patients. It will be a valuable source for cancer researchers, oncologists and several members of biomedical field who are dedicated to better treat patients with colorectal cancer. Presents a systemic summary of molecular mechanisms for a quick and in-depth understanding Updates current trends in the field with pioneering information on drug resistance Encompasses both basic and clinical approaches for a better understanding of unsolved problems from a holistic point-of-view

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance
A Book

by Andrew Freywald,Franco Vizeacoumar

  • Publisher : Academic Press
  • Release : 2020-12-04
  • Pages : 308
  • ISBN : 0128213116
  • Language : En, Es, Fr & De
GET BOOK

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it is so difficult to treat cancer, and why only a very few patients respond to therapy and a significant portion develop resistance. Despite a rapid development of more effective anti-cancer drugs and combination therapies, cancer remains the leading cause of lethality in the developed world. The main reason for this is the ability of heterogeneous subpopulations of tumor cells interacting with constantly evolving tumor microenvironment to resist elimination and eventually, trigger cancer relapse. In this book, experts review current concepts explaining molecular and biological mechanisms of cancer drug resistance and discussing advancing approaches for overcoming these therapeutic challenges. Provides the most updated knowledge on the mechanisms of cancer drug resistance and the emerging therapeutic approaches reviewed by experts in the field Brings detailed analyses of most important recently reported developments related to drug resistance and their relevance to overcoming it in cancer patients Discusses in-depth molecular mechanisms and novel concepts of cancer resistance to conventional and advanced therapies

Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy

Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy
A Book

by Anonim

  • Publisher : Academic Press
  • Release : 2019-11-07
  • Pages : 394
  • ISBN : 0128141417
  • Language : En, Es, Fr & De
GET BOOK

Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy, Volume Seven, describes the fundamental aspects of efflux pumps of the ATP-binding cassette superfamily in cancer resistance pathways, along with strategies to target and improve chemotherapy efficacy. Pumps of the ATP-binding cassette superfamily (ABCs) regulate the access of drugs to the intracellular space. In this context, the overexpression of ABCs is a well-known mechanism of multidrug resistance in cancer and is associated with therapeutic failure. Cancer types discussed include breast, endocrine, hematologic, gastrointestinal, musculoskeletal, lung, skin and central nervous system cancers. The book is a valuable source for researchers and advanced students in cancer, biology, pharmacology, pharmaceutical sciences, biomaterials and medical/clinical sciences that are interested in accessing a comprehensive compendium on efflux pumps in mechanisms of cancer resistance. Offers comprehensive and detailed descriptions of the basic aspects of efflux pumps in a very schematic and didactic manner Describes the involvement of efflux pumps in cancer resistance in different cancer types Encompasses an updated overview on state-of-the-art approaches that capitalize on their inhibition to improve chemotherapy and overcome resistance

Epigenetic Regulation in Overcoming Chemoresistance

Epigenetic Regulation in Overcoming Chemoresistance
A Book

by Chunfu Wu,Lihui Wang

  • Publisher : Academic Press
  • Release : 2021-06-26
  • Pages : 144
  • ISBN : 012823685X
  • Language : En, Es, Fr & De
GET BOOK

Epigenetic Regulation in Overcoming Chemoresistance, Volume 19, explains how epigenetic agents can enhance the chemotherapy sensitivity of diverse types of cancers. The book provides a comprehensive delineation and the recent development of the scientific studies on the epigenetic regulation in enhancing chemo-sensitivity. In addition, it discusses several topics such as DNA methyltransferase inhibitors (DNMTi), Histone deacetylases inhibitors (HDACi), Histone lysine demethylases inhibitors (HDMi), Histone lysine methyltransferases inhibitors (HMTi) and drugs regulating the microRNA, long non-coding RNA (lncRNA) or RNA methylation. Finally, recent and future developments of the field of epigenetic regulation are explored. This is a valuable resource for cancer researchers, clinicians, graduate students and several members of biomedical field who are interested in learning about epigenetic regulation methods to reverse chemo-resistance in cancers. Presents detailed diagrams of the mechanisms of epigenetic regulation for easy consult Encompasses multiple clinical trial summary diagrams to help readers quickly and clearly get information from clinical trials Provides future perspectives in each section to inspire readers to use epigenetic regulation to overcome chemo-resistance

Overcoming Ovarian Cancer Chemoresistance

Overcoming Ovarian Cancer Chemoresistance
A Book

by Goli Samimi,Christina Annunziata

  • Publisher : Academic Press
  • Release : 2020-11-06
  • Pages : 188
  • ISBN : 0128198419
  • Language : En, Es, Fr & De
GET BOOK

Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response Discusses genetic reversions as a unique alteration and a new field of study Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field

Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy

Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy
A Book

by Anonim

  • Publisher : Academic Press
  • Release : 2022-01-26
  • Pages : 294
  • ISBN : 0323905560
  • Language : En, Es, Fr & De
GET BOOK

Anti-angiogenic Drugs as Chemosensitizers in Cancer Therapy, Volume 19 focuses on the use of anti-angiogenic drugs as sensitizers of tumor cells to the inhibitory activity of antitumor agents. Conventional and novel anti-neoplastic agents (cytotoxic molecules, hormones/antihormones, immunotherapies) are taken into consideration, along with advances made in combination therapies. The book encompasses examples of studies on the use of antiangiogenic compounds—molecules that inhibit the growth of vessels inside a tumor—together with antineoplastic drugs in order to sensitize the resistant tumor to their cytotoxic effects, thus reducing adverse side reactions and resistance and improving the therapeutic response of cancer patients. In addition, the book discusses clinical applications in various types of cancer, such as colorectal, lung, breast, renal, genitourinary, skin and brain and circulating tumors. It is a valuable resource for cancer researchers, clinicians and members of the biomedical field who wants to be up-to-date on the most recent and promising developments in the field. Provides the most updated reviews on anti-angiogenic drugs as chemosensitizers by leaders in the field Encompasses summarized tables and schematic diagrams in each chapter to give a clear overview on recent findings in a didactic manner Brings not only relevant information of current research but also new ideas and suggestions for further investigations to help advance the field

Novel Therapies in Head and Neck Cancer: Beyond the Horizon

Novel Therapies in Head and Neck Cancer: Beyond the Horizon
A Book

by Maie A. St. John,No hee Park

  • Publisher : Academic Press
  • Release : 2020-06-29
  • Pages : 266
  • ISBN : 0128209291
  • Language : En, Es, Fr & De
GET BOOK

Novel Therapies in Head and Neck Cancer: Beyond the Horizon, Volume Twelve, provides a high-level synthesis of the latest treatments and outcomes relating to head and neck cancer. Chemotherapy and immunotherapy for those cancer types are rapidly evolving, and an updated source based on the expertise of internationally renowned researchers is necessary. This book discusses the outcome of recent trials using chemotherapy, novel approaches for HPV+ SCCA, cases in which immunotherapy is more likely to be successful, and precision medicine based on target therapies. Additionally, new approaches for rare diseases in head and neck and novel drug delivery platforms are presented. This book will be a very useful source so that students, scientists and clinicians who can be facile with the data, build on what is known, and continue to offer cutting-edge, validated therapies to all patients. Covers new chemotherapy trials, specifically on HPV and non-HPV related cancer types Discusses the application of immunotherapy to treat rare types of head and neck cancer Presents updated information on targeted therapies, specifically focusing on skin cancer in the region

pH-Interfering Agents as Chemosensitizers in Cancer Therapy

pH-Interfering Agents as Chemosensitizers in Cancer Therapy
A Book

by Claudiu Supuran,Simone Carradori

  • Publisher : Academic Press
  • Release : 2020-09-15
  • Pages : 228
  • ISBN : 0128209283
  • Language : En, Es, Fr & De
GET BOOK

pH Interfering Agents as Chemosensitizers In Cancer Therapy, Volume Thirteen, provides a detailed overview of the chemosensitizers for the treatment of cancer spanning from biochemical and structural features to pharmacology and drug-design, including technological applications. The book is structured with innovative outlines and a distinction between experimental and clinical results. The continuous discovery and assessment of the role played by old/new synthetic drugs, natural compounds and technological applications has led to the urgent need of classification in terms of biological activity, mechanism of action, clinical outcomes, cancer cell lines sensible to the treatment, and potentialities to better orient research in this field. Moreover, all the aspects relevant for medicinal chemistry (drug design, structure-activity relationships, permeability data, cytotoxicity, appropriate statistical procedures, and molecular modeling studies) are strictly considered. Presents a broad view of the topic according to a medicinal chemistry-based approach beyond syntheses and biological assays, focusing on SAR studies, chemoinformatic, drug targeting and molecular modeling Explains the mechanism of action of the chemosensitizers by means of schemes and figures to facilitate comprehension Discusses novel targets to explore new possibilities that enhance research in the field

Avastin and Malignant Gliomas

Avastin and Malignant Gliomas
A Book

by Thomas C. Chen,Marc C. Chamberlain

  • Publisher : Bentham Science Publishers
  • Release : 2010-12-28
  • Pages : 195
  • ISBN : 9781608051328
  • Language : En, Es, Fr & De
GET BOOK

"Neuro-oncology is an embryonic field of cancer research with a number of clinical trials in progress. However, the prognosis on neuro-oncologic patients has remained poor. Moreover, several small scale phase I/II trials performed have proved to be inconcl"

In Vitro Models of Glioblastoma Targeting Cancer Metabolism

In Vitro Models of Glioblastoma Targeting Cancer Metabolism
A Book

by Alexander Wilding

  • Publisher : Unknown Publisher
  • Release : 2014
  • Pages : 472
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Glioblastoma (GBM) is a highly lethal and incurable primary tumour of the brain and central nervous system (CNS). While the genetic alterations in GBM are highly heterogeneous, most tumours exhibit changes promoting activation of RTK signalling and inactivation of Rb and p53 signalling pathways. As with other cancer types, the metabolism of rapidly proliferating tumour cells in GBM is dramatically different to that of their normal, non-proliferating counterparts. The most notable alteration is that of 'aerobic glycolysis', the propensity to metabolise glucose to lactate, even in the presence of oxygen. These changes are believed to support the increased proliferation rate and resistance to therapy that typify this and other types of cancer. Our understanding of how metabolic changes support tumour growth is still poor. Nevertheless, the conservation of these changes across diverse tumour types highlights their importance and suggests that cancer metabolism is a potential therapeutic target. In particular PKM2, an isozyme of the glycolytic enzyme pyruvate kinase is highly expressed in most cancers including GBM and appears to facilitate many metabolic features of cancer including aerobic glycolysis. Universal expression of PKM2 in cancer makes it an appealing target for therapy and both activators and inhibitors of PKM2 have been investigated as potential therapeutic options.Using in vitro models, this thesis explores the effects of a number of compounds that target or otherwise modulate cell metabolism. It is hoped that an understanding of how these compounds affect cancer cell metabolism will contribute to the development of novel therapeutic strategies for the treatment of glioma, as well as other cancers.In Chapter 3, a methodology is developed for assaying the anti-proliferative effects of combinations of drugs on glioma cells in vitro, comparing different approaches to assess antagonistic and synergistic drug interactions.In Chapter 4 of this dissertation, the factors that regulate tetramer formation and catalytic activity of PKM2 were examined in glioblastoma cell lines. Novel methods for the detection of PKM2 complex formation, pyruvate kinase activity and glycolytic rate were developed. The ability of a novel PKM2 activator to induce PKM2 tetramer formation and catalytic activity was assesses. We then attempted to exploit the effects of the PKM2 activator to affect cell metabolism in an attempt to identify a therapeutic application of pharmacologic PKM2 activation. In Chapter 5, investigating the effects of TORC1 inhibition using Temsirolimus on PKM2 tetramer formation led to the observation that TORC1 inhibition results in rapid inhibition of glycolysis and a reversal of the Crabtree effect. While the precise target could not be identified, glucose metabolism appeared to be at the level of hexokinase or glucose transport, as both glycolysis and the PPP were affected. We then go on to demonstrate that this block in glucose metabolism induces a striking sensitivity to oxidative stress as would be encountered by glioma cells exposed to IR therapy.In Chapter 6, the multi-kinase inhibitor Sorafenib was identified as exhibiting rapid and potent inhibitory effects on mitochondrial function in glioma cells leading to a reliance on glycolysis for ATP production. Detailed analysis of mitochondrial respiratory function the utility of simultaneous inhibition of respiration and glycolysis using Sorafenib and the glycolysis inhibitor 2-deoxyglucose as a therapeutic strategy is then evaluated in vitro and in vivo.

Resistance to Targeted Therapies Against Adult Brain Cancers

Resistance to Targeted Therapies Against Adult Brain Cancers
A Book

by Amanda Tivnan

  • Publisher : Springer
  • Release : 2016-11-26
  • Pages : 260
  • ISBN : 3319465058
  • Language : En, Es, Fr & De
GET BOOK

This volume will bring together a review of research being carried out by international experts in this field, detailing treatment and research approaches in several forms of malignant brain tumors. These include glioblastoma (GBM), a highly aggressive and fatal form of astrocytoma which accounts for 80% of newly diagnosed brain tumor patients per year, and meningioma, of which 10% are malignant and extremely resistant to targeted therapies. The volume will also include a discussion of methods to overcome blood-brain barrier exclusion for more efficient targeted drug delivery in all forms of brain cancer treatment. The volume will include information on the repurposing of drugs in an attempt to circumvent drug resistance, use of small molecule inhibitors in GBM treatment, mechanisms of secondary brain metastasis, drug resistance, and state-of-the-art imaging of targeted therapies.

Glioblastoma: State of the Art and Future Perspectives

Glioblastoma: State of the Art and Future Perspectives
A Book

by Ghazaleh Tabatabai ,Hiroaki Wakimoto

  • Publisher : MDPI
  • Release : 2020-12-10
  • Pages : 784
  • ISBN : 3039282603
  • Language : En, Es, Fr & De
GET BOOK

Glioblastoma is an aggressive incurable primary tumor of the central nervous system. Median overall survival is in the range of 1.5 years even in selected clinical trials populations. Many features contribute to this therapeutic challenge including high intratumoral and intertumoral heterogeneity, resistance to therapy, migration and invasion, immunosuppression. With the access of novel highthroughput technologies, significant progress has been made to understand molecular and immunological signatures underlying the pathology of glioblastoma. Clinical trial designs have shifted from investigating broad “one-for-all” treatment approaches to precision oncology designs. The collection of contributions in this book aim at providing researchers and clinicians an update on different aspects of glioblastoma, i.e. progress in basic, preclinical and clinical research.

Drug Resistance in Cancer Cells

Drug Resistance in Cancer Cells
A Book

by Kapil Mehta,Zahid H. Siddik

  • Publisher : Springer Science & Business Media
  • Release : 2009-06-12
  • Pages : 363
  • ISBN : 9780387894454
  • Language : En, Es, Fr & De
GET BOOK

It was estimated that in 2008, 1,437,180 patients would receive a new cancer diagnosisand 565,650individualswould die of cancer (Jemal et al. 2008).Since the vast majority of patients dying of cancer will have had anticancer therapy, both c- ventional chemotherapy and novel targeted therapy, it can be concluded that these patients are dying with drug resistant cancer. The term multidrug resistance is also apt – in that these patients die after having undergone multiple rounds of different and structurally unrelated cancer therapies. However, for some, the concept of m- tidrug resistance is a worn out idea, stemming from disappointment with the drug resistancereversalstrategiesthatwerecarriedoutinthe1990susingpumpinhibitors to block drug resistance mediated by P-glycoprotein, product of the MDR-1 gene. However, if one takes the larger de?nition – multidrug resistance as simultaneous resistance to multiple structurally unrelated anticancer therapies – its existence c- not be denied. The purpose of this book is to explore new concepts related to drug resistance in cancer, including resistance to the new molecularly targeted agents. Perhaps new terminology is needed for resistance that occurs following therapy with the targeted agents: Novel Targeted Agent Resistance (NTR). Alternatively, we can return to the original de?nition of multidrug resistance as simply the res- tance to multipleagents that occurs in the course of normalcancer progression.This resistance is likely to be mediated by many factors.

Radiobiology of Glioblastoma

Radiobiology of Glioblastoma
Recent Advances and Related Pathobiology

by Luigi Pirtoli,Giovanni Luca Gravina,Antonio Giordano

  • Publisher : Springer
  • Release : 2016-06-06
  • Pages : 305
  • ISBN : 3319283057
  • Language : En, Es, Fr & De
GET BOOK

This text properly considers the most recent and relevant advances in molecular RB of GB, taking into account the related topics of pathobiology, and underscores the most promising translational perspectives from the preclinical to the clinical domain. Section I (From Bedside to Bench) discusses conditions associated with RT resistance of GB and the consequent RB hints, technology improvements intended to overcome RT-resistance of GB, mathematical modeling of RB parameters from clinical studies, the present impact of molecular prognostic factors in therapy of GB, and RT tolerance of normal brain. Section II (Preclinical Research and Pathobiology Topics) presents the traditional and mechanistic/molecular approaches to RB of GB, genetic and epigenetic studies on GB, issues of cell-death pathways, stem-like cells, invasiveness, tumor microenvironment, hypoxia, mi-RNA manipulations, and nanoparticle technology. Section III (Translational Perspectives) presents RB issues related to molecular profiling and classification of GB as frames of reference for clinical studies, translational perspectives of gene therapy, evolving protocols based on pre-clinical data and large data-bases and ontologic models. Radiobiology of Glioblastoma: Recent Advances and Related Pathobiology will be of great value to pathologists, medical oncologists, radiation oncologists as well as basic researchers and clinical investigators.

New Advances on Disease Biomarkers and Molecular Targets in Biomedicine

New Advances on Disease Biomarkers and Molecular Targets in Biomedicine
A Book

by Nikki P. Lee,C.Y. Cheng,John M. Luk

  • Publisher : Springer Science & Business Media
  • Release : 2013-06-22
  • Pages : 275
  • ISBN : 1627034560
  • Language : En, Es, Fr & De
GET BOOK

Rising occurrences of various diseases and epidemics have pressurized the already-burdened health system across the globe, and this imposes an unprecedented challenge on our current research in identifying disease-specific biomarkers and molecular targets, in particular for cancers, neurological disorders and unexplained infertility. Despite decades of efforts in deciphering the fundamental biology underlying various diseases at discrete levels using an array of advanced technologies, attempts to identify reliable and disease-indicating markers for detection and biomolecules or cellular structures for targeting are still in vain. This monograph describes and discusses the updated findings in this field with a specific aim to compile prior and recent literature and from there to acquire some insights to facilitate future research to expand options of understanding, detecting and treating diseases. Among the many possible areas of biomedical research, this content comprises two themes: disease biomarkers and molecular targets. The book also covers topics that are more advanced in development to emerging scientific discoveries. In particular, this monograph includes concepts on the renovated use of oncofetal molecules in cancer prediction and treatment, the evolving development in cancer biology at the cellular and molecular levels and the recent involvement on new classes of molecules in diseases. This book renews established concepts in the field, and at the same time leads to important insights for research and development of drugs, diagnostics, and interventions for managing diseases of unmet medical needs.

Targeting Developmental Pathways in Inflammation and Disease

Targeting Developmental Pathways in Inflammation and Disease
A Book

by Maria Pia Felli,Lisa M. Minter,Eleni Anastasiadou

  • Publisher : Frontiers Media SA
  • Release : 2022-01-05
  • Pages : 129
  • ISBN : 2889719464
  • Language : En, Es, Fr & De
GET BOOK